// App-Quantinova.ai

: Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Rebecca J Nagy

  • A. Oliver Sartor

  • Gregory Russell Pond

  • Theodore Stewart Gourdin

  • Lakshminarayanan Nandagopal

  • Elisa M. Ledet

  • Neeraj Agarwal

  • Emma Carroll

  • Gurudatta Naik

  • Jue Wang

  • Mehmet Asim Bilen

  • Petros Grivas

  • Richard B. Lanman

  • Amirali Talasaz

  • Michael B. Lilly

Medical Centers

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Guardant Health, Rewdwood City, CA

  • Tulane University, New Orleans, LA

  • Ontario Clinical Oncology Group, Hamilton, ON, Canada

  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • University of Alabama at Birmingham, Boston, MA.

  • Tulane Cancer Center, New Orleans, LA

  • Huntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • University of Alabama at Birmingham, Birmingham, AL

  • University of Arizona Cancer Center at DH-SJHMC, Phoenix, AZ

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Medcl Univ of South Carolina, Charleston, SC

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating DNA

  • Plasma cell-free DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved